Remdesivir Remivir Injection 100 mg

Remdesivir Remivir Injection 100 mg

COVID 19 Drugs

Description : Remdesivir  is a prescribed drug used in treatment of Coronavirus disease (COVID-19). It has shown to be effective in managing hospitalized patients suffering from severe Covid-19 infection. To buy ‘Remdesivir ‘ or to know its price contact India’s leading wholesaler and exporter 3S Corporation.

Side Effect : Common side effects of Remdesivir   may include fever, kidney damage, anemia, nausea, vomiting, hypotension and increased liver enzymes.

Dosage : Recommended  Adult Dose for COVID-19 – For investigational use only
Loading dose (Day 1): 200 mg IV as a single dose
Maintenance dose (from Day 2): 100 mg IV once a day
Duration of Therapy:
-Invasive mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO) required: 10 days total
-Invasive mechanical ventilation and/or ECMO not required: 5 days total; may extend up to 5 additional days (i.e., up to 10 days total) if no clinical improvement shown

Recommended Pediatric Dose for COVID-19 – For investigational use only
Body weight 3.5 to less than 40 kg: Loading dose (Day 1): 5 mg/kg IV as a single dose
-Maintenance dose (from Day 2): 2.5 mg/kg IV once a day
Body weight at least 40 kg: Loading dose (Day 1): 200 mg IV as a single dose
-Maintenance dose (from Day 2): 100 mg IV once a day
Duration of Therapy:
-Invasive mechanical ventilation and/or ECMO required: 10 days total
-Invasive mechanical ventilation and/or ECMO not required: 5 days total; may extend up to 5 additional days (i.e., up to 10 days total) if no clinical improvement shown

Renal Dose Adjustments  Adult and pediatric patients (older than 28 days):
-Estimated glomerular filtration rate (eGFR) less than 30 mL/min: Not recommended unless benefit outweighs risk.
Full-term neonates (7 to 28 days old):
-Serum creatinine at least 1 mg/dL: Not recommended unless benefit outweighs risk.

Liver Dose Adjustments – Should only be used if benefit outweighs risk
-If ALT at least 5 times the upper limit of normal (5 x ULN) at baseline: This drug should not be started.
During therapy:
-If develop ALT at least 5 x ULN: This drug should be discontinued; it may be restarted when ALT is less than 5 x ULN.
-If develop ALT elevation with signs/symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR: This drug should be discontinued.

Storage : Store vials in refrigerator (2C to 8C [36F to 46F]) until needed for use.

FDA Approved : n/a

 

Jenisha Kumar
Date

December 12, 2020

No Comments

Leave a Reply